Endonovo Therape (ENDV) Financials

ENDV

Trailing 12 months to September 30, 2023

Revenue $256K +1699.9% YoY

Net Income Not reported for the trailing 12 months

Operating Cash Flow -$630K +25.4% YoY

Gross Profit $246K +110229.1% YoY

Market Cap $145K as of Sep 3, 2026

Price / Sales 0.6x on $256K revenue, trailing 12 months to September 30, 2023

Price / Earnings n/m no net income reported

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2023

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2023, ended Sep 30, 2023 Reported Dec 29, 2023 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2023, filed Dec 29, 2023. Each column of the statement tables below links to the filing it was taken from.

Endonovo Therape (ENDV) reported $256K in revenue over the twelve months to Sep 30, 2023, up 1699.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENDV FY2022 2026-08-30

Endonovo’s dominant mechanic is a tiny revenue base supporting persistent operating losses while liabilities overwhelm shrinking assets and liquidity.

Revenue peaked at $310K in FY2019, yet FY2022 operating losses were $3.3M, indicating the expense base remained largely disconnected from sales volume. Gross profit margin rose from 84.5% in FY2018 to 92.6% in FY2022, but that improved unit economics did not translate into operating break-even; the business retained a structurally heavy overhead load.

By FY2022, liabilities had reached $33.5M against $1.3M of assets, leaving negative equity rather than a conventional capital cushion. The 0.0005x current ratio and 0 months of reported liquidity describe near-term resources as negligible relative to obligations, making external financing central to the operating structure.

Operating cash outflow narrowed from $2.9M in FY2018 to $679K in FY2022, a meaningful cash-use reduction despite the lack of operating profitability. FY2022 financing inflow of $593K alongside negative operating cash flow indicates the improvement was not self-funded; funding still supplemented operations.

Financial Health Signals

Financial health score not available

Endonovo Therape does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-121.63

Endonovo Therape scores -121.63, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($145K) relative to total liabilities ($33.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/6

Endonovo Therape passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Interest Coverage At Risk

N/A

Endonovo Therape reported an operating loss of $3.3M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2K

YoY-86.1%

QoQ-96.6%

5Y CAGR-41.0%

Endonovo Therape generated $2K in revenue in Q3 2023. This represents a decrease of 86.1% from the same quarter a year earlier. Against the prior quarter it is down 96.6%.

EBITDA

-$311K

YoY+7.2%

Endonovo Therape's EBITDA was -$311K in Q3 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.2% from the same quarter a year earlier.

Net Income

-$766K

YoY-27.0%

QoQ-137.1%

Endonovo Therape reported -$766K in net income in Q3 2023. This represents a decrease of 27.0% from the same quarter a year earlier. Against the prior quarter it is down 137.1%.

EPS (Diluted)

$0.00

QoQ+100.0%

Endonovo Therape earned $0.00 per diluted share (EPS) in Q3 2023. Against the prior quarter it is up 100.0%.

Cash & Balance Sheet

Cash & Debt

YoY-100.0%

QoQ-100.0%

Endonovo Therape held $0 in cash against $7.1M in long-term debt as of Q3 2023.

Shares Outstanding

319M

YoY+64.0%

QoQ+0.3%

Endonovo Therape had 319M shares outstanding in Q3 2023. This represents an increase of 64.0% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Free Cash Flow

Not reported for Q3 2023.

Dividends Per Share

Not reported for Q3 2023.

Margins & Returns

Gross Margin

45.6%

YoY-17.7pp

QoQ-54.4pp

5Y CAGR-34.2pp

Endonovo Therape's gross margin was 45.6% in Q3 2023, indicating the percentage of revenue retained after direct costs. This is down 17.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 54.4 percentage points.

Operating Margin

Not shown for Q3 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2023.

Capital Allocation

None of these metrics is reported for Q3 2023.

ENDV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENDV quarterly income statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	$256K	$135K+85.2%	$73K-55.9%	$166K-46.5%	$310K+272.5%	$83K	N/A	N/A	$4K-82.4%	$24K+5.7%	$23K-25.1%	$31K-32.9%	$46K-11.0%	$51K
Cost of Revenue	N/A	$10K-33.3%	$15K-77.1%	$65K-30.0%	$93K+622.2%	$13K	N/A	N/A	$2K-86.0%	$15K+10.7%	$14K	N/A	N/A	N/A
Gross Profit	$246K	$125K+115.7%	$58K-42.1%	$100K-53.7%	$217K+208.2%	$70K	N/A	N/A	$2K-75.8%	$9K-2.2%	$9K	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$0-100.0%	$3K-97.9%	$153K-44.2%	$274K+138.2%	$115K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$2.6M	-$3.3M-46.6%	-$2.2M+23.5%	-$2.9M+23.5%	-$3.8M+8.4%	-$4.2M+9.7%	-$4.6M	N/A	N/A	N/A	N/A	N/A	-$96K-22.5%	-$78K
EBITDA	N/A	-$2.6M-65.9%	-$1.6M+30.2%	-$2.3M+28.4%	-$3.2M+10.0%	-$3.5M+23.5%	-$4.6M	N/A	N/A	N/A	N/A	N/A	-$95K-22.8%	-$77K
Interest Expense	-$1.2M	-$1.3M-240.4%	$942K-54.8%	$2.1M+12153.4%	$17K+100.3%	-$5.2M+10.2%	-$5.8M	N/A	-$1.5M-762.2%	-$179K+33.2%	-$268K-135.6%	-$114K-5207.9%	$2K-76.3%	$9K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$532	$0-100.0%	$8000.0%	$800
Net Income	N/A	N/A	-$3.1M-684.9%	-$396K	N/A	-$6.4M+40.5%	-$10.8M	N/A	N/A	N/A	N/A	N/A	-$94K-35.6%	-$69K
EPS (Basic)	N/A	-$0.13-160.0%	-$0.05	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Revenue	$2K-86.1%	$45K+6853.8%	$88K+3736.1%	$121K+38337.7%	$11K+40.7%	$650-97.9%	$2K-93.4%	$316-97.3%
Cost of Revenue	$827-79.5%	N/A	$4K+459.7%	$5K-45.1%	$4K+29.8%	$383-23.4%	$714-71.7%	$9K-81.2%
Gross Profit	$693-90.0%	$45K+16828.8%	$84K+5228.1%	$117K+1464.5%	$7K+47.9%	$267-99.1%	$2K-95.1%	-$9K+76.0%
Operating Income	-$473K+4.8%	-$1.1M+37.1%	-$529K-9.0%	-$483K-29.2%	-$497K+28.2%	-$1.8M-215.5%	-$486K+17.7%	-$374K+45.3%
EBITDA	-$311K+7.2%	N/A	N/A	-$321K-51.5%	-$335K+36.8%	-$1.6M-300.9%	-$324K+24.1%	-$212K+59.3%
Interest Expense	-$286K+15.6%	-$313K+7.3%	-$309K+8.0%	-$309K-118.7%	-$339K-37.3%	-$338K-180.8%	-$336K+3.2%	$1.7M-54.2%
Net Income	-$766K-27.0%	$2.1M+181.7%	N/A	N/A	-$603K+60.4%	-$2.5M-94.8%	-$2.4M+10.0%	$2.4M+218.0%
EPS (Basic)	$0.00	$0.00+100.0%	$0.03+200.0%	-$0.08-260.0%	$0.00+100.0%	-$0.020.0%	-$0.03+50.0%	$0.05
EPS (Diluted)	$0.00	-$0.01+50.0%	$0.00+100.0%	N/A	$0.00	-$0.02	-$0.03	N/A
Diluted Shares (Avg)	1.35B+779.4%	1.35B+905.3%	1.74B+2106.3%	N/A	154M	134M	79M	N/A

Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, Income Tax.

ENDV Balance Sheet

ENDV quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$1.3M-36.2%	$2.0M-23.0%	$2.6M-20.4%	$3.3M-22.8%	$4.2M-8.0%	$4.6M+1347.3%	$319K-22.2%	$409K+797.9%	$46K-38.1%	$74K-5.8%	$78K-92.1%	$994K+491.6%	$168K
Current Assets	$16K-83.3%	$95K+105.4%	$46K-26.2%	$63K-83.6%	$382K+244.1%	$111K-63.3%	$303K-19.8%	$378K+12540.8%	$3K-8.2%	$3K+306.9%	$800-91.5%	$9K-94.3%	$165K
Cash & Equivalents	$98-99.9%	$86K+540.4%	$13K-29.0%	$19K-95.0%	$379K+320.5%	$90K+62.4%	$56K+33.9%	$41K+4097.7%	$988-69.6%	$3K+306.9%	$800-91.3%	$9K	$0
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	$944+0.2%	$942-95.9%	$23K+579.9%	$3K	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Total Liabilities	$33.5M+88.2%	$17.8M+4.7%	$17.0M-28.6%	$23.8M+52.1%	$15.6M+10.4%	$14.2M+59.5%	$8.9M-8.3%	$9.7M+104.4%	$4.7M+12.7%	$4.2M+67.0%	$2.5M+74.8%	$1.4M+75731.5%	$2K
Current Liabilities	$33.4M+88.6%	$17.7M+5.2%	$16.8M-28.8%	$23.6M+52.6%	$15.5M+15.4%	$13.4M+53.8%	$8.7M-8.1%	$9.5M+108.3%	$4.6M+13.6%	$4.0M+128.7%	$1.8M+153.7%	$691K+36257.8%	$2K
Non-Current Liabilities	$80K0.0%	$80K-48.5%	$155K0.0%	$155K0.0%	$155K-79.4%	$753K+373.0%	$159K-20.1%	$199K+8.5%	$184K-7.0%	$197K-74.2%	$766K+2.1%	$750K	$0
Long-Term Debt	$7.2M-1.4%	$7.3M+6.2%	$6.8M-0.6%	$6.9M-15.7%	$8.2M+10.9%	$7.4M+130.3%	$3.2M+11048.3%	$29K-98.2%	$1.6M	N/A	N/A	N/A	N/A
Total Equity	-$32.2M-104.0%	-$15.8M-9.7%	-$14.4M+29.9%	-$20.5M-80.0%	-$11.4M-19.3%	-$9.6M-11.5%	-$8.6M+7.7%	-$9.3M-97.7%	-$4.7M-13.6%	-$4.1M-69.3%	-$2.4M-445.7%	-$447K-369.3%	$166K
Retained Earnings	-$75.1M-33.1%	-$56.4M-5.8%	-$53.3M-0.8%	-$52.9M-48.6%	-$35.6M-22.1%	-$29.2M-58.8%	-$18.4M-40.7%	-$13.1M-107.5%	-$6.3M-18.0%	-$5.3M-118.5%	-$2.4M-364.0%	-$526K-7.2%	-$491K

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Total Assets	$816K-43.8%	$1.0M-36.4%	$1.2M-33.9%	$1.3M-36.2%	$1.5M-32.1%	$1.6M-29.9%	$1.8M-28.0%	$2.0M-23.0%
Current Assets	$36K+47.4%	$73K+1125.1%	$95K+47.7%	$16K-83.3%	$24K-61.5%	$6K-84.6%	$64K-48.1%	$95K+105.4%
Cash & Equivalents	$0-100.0%	$33K	$11K-81.8%	$98-99.9%	$23K+303.7%	$0-100.0%	$60K-30.2%	$86K+540.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	$3K+230.2%	N/A	$944-86.7%	$945-90.0%	$945-87.4%	$944+0.2%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$23.8M+12.9%	$23.4M+12.9%	$25.6M+28.8%	$33.5M+88.2%	$21.1M+3.4%	$20.8M+7.8%	$19.9M+7.3%	$17.8M+4.7%
Current Liabilities	$23.7M+13.0%	$23.1M+11.9%	$25.5M+28.9%	$33.4M+88.6%	$21.0M+3.5%	$20.7M+7.8%	$19.8M+7.8%	$17.7M+5.2%
Non-Current Liabilities	$80K0.0%	$290K+263.2%	$80K0.0%	$80K0.0%	$80K0.0%	$80K0.0%	$80K-48.5%	$80K-48.5%
Long-Term Debt	$7.1M-2.5%	$7.1M-4.8%	$6.9M-6.2%	$7.2M-1.4%	$7.3M+6.6%	$7.4M+10.1%	$7.4M+7.6%	$7.3M+6.2%
Total Equity	-$23.0M-17.1%	-$22.4M-17.0%	-$24.4M-35.1%	-$32.2M-104.0%	-$19.6M-7.6%	-$19.2M-12.8%	-$18.0M-12.9%	-$15.8M-9.7%
Retained Earnings	-$66.6M-7.5%	-$65.9M-7.3%	-$67.9M-15.4%	-$75.1M-33.1%	-$62.0M-5.3%	-$61.4M-7.1%	-$58.9M-5.1%	-$56.4M-5.8%

Not reported in any period shown, so not listed: Inventory, Goodwill.

ENDV Cash Flow Statement

ENDV quarterly cash flow statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	-$630K	-$679K+31.2%	-$987K-33.0%	-$742K+70.8%	-$2.5M+11.7%	-$2.9M+3.7%	-$3.0M	N/A	-$1.0M	N/A	-$257K+9.6%	-$285K-465.8%	-$50K-692.3%	$9K
Depreciation & Amortization	N/A	$647K-0.2%	$648K-0.4%	$651K+0.1%	$650K0.0%	$650K+4305.0%	$15K-6.8%	$16K+7.2%	$15K-6.1%	$16K+31.5%	$12K-67.7%	$37K+3682.8%	$979+1.6%	$964
Stock-Based Compensation	N/A	$45K	$0-100.0%	$57K+85.1%	$31K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	$3K-71.1%	$9K	N/A	N/A	$4K	$0	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$2.5M+11.9%	-$2.9M	N/A	N/A	-$1.0M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	-$3K+71.1%	-$9K+99.7%	-$3.0M	N/A	-$4K	$0-100.0%	$4K-63.9%	$11K	N/A	N/A
Financing Cash Flow	$607K	$593K-44.0%	$1.1M+43.9%	$736K-66.3%	$2.2M-31.3%	$3.2M-47.3%	$6.0M	N/A	$1.1M	N/A	$256K-11.1%	$288K+237.2%	$85K+471.4%	-$23K

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Operating Cash Flow	-$65K+47.2%	-$166K+19.7%	-$173K-40.8%	-$226K+42.4%	-$124K+26.9%	-$206K-51.9%	-$123K+57.6%	-$391K-102.9%
Depreciation & Amortization	$162K0.0%	N/A	N/A	$162K0.0%	$162K0.0%	$162K0.0%	$162K-1.0%	$162K-0.6%
Stock-Based Compensation	N/A	N/A	$3K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$33K-77.7%	$188K+28.0%	$184K+89.7%	$203K-57.1%	$147K-11.8%	$147K+150.4%	$97K-73.2%	$472K+131.5%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

ENDV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENDV quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Gross Margin	92.6%+13.1pp	79.5%+18.9pp	60.6%-9.3pp	69.9%-14.6pp	84.5%	N/A	N/A	49.3%+13.3pp	36.0%-2.9pp	38.9%	N/A	N/A	N/A
Operating Margin	-2411.7%	-3045.7%	-1756.5%	-1228.1%	-4995.3%	N/A	N/A	N/A	N/A	N/A	N/A	-209.7%	-152.3%
Net Margin	N/A	-4247.2%	-238.6%	N/A	-7729.5%	N/A	N/A	N/A	N/A	N/A	N/A	-206.6%	-135.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-41.8%
Return on Assets	N/A	-154.7%-139.5pp	-15.2%	N/A	-151.7%+82.7pp	-234.4%	N/A	N/A	N/A	N/A	N/A	-9.5%+31.9pp	-41.3%
Current Ratio	0.000.0x	0.010.0x	0.000.0x	0.000.0x	0.020.0x	0.010.0x	0.030.0x	0.040.0x	0.000.0x	0.000.0x	0.000.0x	0.01-86.7x	86.74
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.01
Asset Turnover	0.11+0.1x	0.040.0x	0.060.0x	0.09+0.1x	0.02	N/A	N/A	0.01-0.5x	0.53+0.2x	0.31-0.1x	0.39+0.3x	0.05-0.3x	0.30
FCF Margin	N/A	N/A	N/A	-820.1%	-3468.3%	N/A	N/A	-23989.8%	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Gross Margin	45.6%-17.7pp	100.0%+58.9pp	95.4%+26.7pp	96.0%	63.3%+3.1pp	41.1%-57.3pp	68.7%-24.0pp	-2704.1%
Operating Margin	-31105.1%	-2502.9%	-604.6%	-397.7%	-4532.7%	-276730.6%	-21286.7%	-118289.2%
Net Margin	-50405.9%	4565.6%	N/A	N/A	-5505.1%	-388635.5%	-105749.7%	758332.3%
Return on Assets	-93.9%-52.3pp	203.4%+361.7pp	N/A	N/A	-41.6%+29.7pp	-158.4%-101.4pp	-133.0%-26.6pp	119.4%+197.3pp
Current Ratio	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.010.0x
Asset Turnover	0.000.0x	0.040.0x	0.07+0.1x	0.09+0.1x	0.010.0x	0.000.0x	0.000.0x	0.000.0x

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$32.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Endonovo Therape ENDV	FY2022	$135K	N/A	N/A	$145K	—
Trevena Inc TRVN	FY2023	N/A	-$40.3M	N/A	$1.3M	—
Scorpius Holdings SCPX	FY2024	$6.2M	-$32.8M	N/A	$1.5M	—
Vincerx Pharma Inc VINC	FY2024	N/A	-$30.1M	N/A	$3.5M	—

Where Endonovo Therape Ranks

Frequently Asked Questions

What is Endonovo Therape's annual revenue?

Endonovo Therape (ENDV) reported $135K in total revenue for fiscal year 2022. This represents a 85.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Endonovo Therape's revenue growing?

Endonovo Therape (ENDV) revenue grew by 85.2% year-over-year, from $73K to $135K in fiscal year 2022.

What is Endonovo Therape's EBITDA?

Endonovo Therape (ENDV) had EBITDA of -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Endonovo Therape have?

As of fiscal year 2022, Endonovo Therape (ENDV) had $98 in cash and equivalents against $7.2M in long-term debt.

What is Endonovo Therape's gross margin?

Endonovo Therape (ENDV) had a gross margin of 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is Endonovo Therape's operating cash flow?

Endonovo Therape (ENDV) recorded an outflow of $679K in operating cash flow during fiscal year 2022, representing cash used by core business activities.

What are Endonovo Therape's total assets?

Endonovo Therape (ENDV) had $1.3M in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does Endonovo Therape have outstanding?

Endonovo Therape (ENDV) had 270M shares outstanding as of fiscal year 2022.

What is Endonovo Therape's current ratio?

Endonovo Therape (ENDV) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Endonovo Therape's P/E ratio?

Endonovo Therape (ENDV) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $145K as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Endonovo Therape's price-to-sales ratio?

Endonovo Therape (ENDV) trades at 0.6x sales, its market capitalization divided by revenue of $256K revenue, trailing 12 months to September 30, 2023. The market capitalization is $145K as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Endonovo Therape's liquidity compare with its operating cash outflow?

At the end of fiscal year 2022, Endonovo Therape (ENDV) held $98 in cash, cash equivalents and investments, and reported an operating cash outflow of $679K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Endonovo Therape's debt-to-equity ratio negative or not reported?

Endonovo Therape (ENDV) has negative shareholder equity of -$32.2M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Endonovo Therape's Altman Z-Score?

Endonovo Therape (ENDV) has an Altman Z-Score of -121.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Endonovo Therape's Piotroski F-Score?

Endonovo Therape (ENDV) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can Endonovo Therape cover its interest payments?

Endonovo Therape (ENDV) reported an operating loss of $3.3M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.